Related Experiment Video
Updated: Oct 8, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
Characteristics and Outcomes of Candidemia in Patients with Durable Left Ventricular Assist Device Support
Kaitlyn L Broderick1, Carli J Peters1, Jeremy A Mazurek2
1From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract:
There are limited data on the characteristics and clinical course of fungal infections in patients on durable left ventricular assist device (LVAD) support. We sought to further characterize the epidemiology and outcomes of LVAD patients with fungemia. We performed a retrospective review of patients receiving LVAD support from January 2012 through June 2020 at a large academic institution. Among 336 patients on LVAD support, five (1.4%) were diagnosed with fungemia during the study period. Three patients had diabetes with mean hemoglobin A1c 7.1% (R 6.6, 7.4). Fever and leukocytosis (mean white blood count 17.0 thousand/µL [R 12.5, 29.9]) were the most common symptoms. Fungemia was diagnosed early after LVAD implantation (mean 14.4 support days [R 2, 19]). All patients were infected with Candida species, and four isolates were susceptible to fluconazole. Central nervous system outcomes included an ischemic stroke, subarachnoid hemorrhage, and malignant hemorrhagic stroke. Two patients were successfully transplanted, and two patients on destination therapy remain on suppressive fluconazole. In conclusion, fungemia is a rare and severe complication in LVAD patients occurring early postimplant.
Insights
Fungal infections (fungemia) are rare but severe complications in patients with durable left ventricular assist devices (LVADs). This study found fungemia occurred early after LVAD implantation and was associated with serious neurological events.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Device Research
Background:
- Limited data exist on fungal infections in patients with durable left ventricular assist device (LVAD) support.
- Fungal infections (fungemia) can be a severe complication in immunocompromised patients and those with indwelling medical devices.
Purpose of the Study:
- To characterize the epidemiology and clinical outcomes of fungemia in patients with LVAD support.
- To identify risk factors and common pathogens associated with fungemia in this population.
Main Methods:
- Retrospective review of patients with LVAD support from January 2012 to June 2020 at a large academic institution.
- Analysis of patient demographics, clinical presentation, causative fungal species, treatment, and outcomes.
Main Results:
- Fungemia occurred in 1.4% (5/336) of LVAD patients, diagnosed early post-implantation (mean 14.4 days).
- Candida species were the causative agents, with most isolates susceptible to fluconazole.
- Neurological complications, including stroke, were observed. Two patients were transplanted, and two remained on suppressive therapy.
Conclusions:
- Fungemia is a rare, severe, and early complication in LVAD patients.
- Prompt diagnosis and appropriate antifungal therapy are crucial for managing fungemia in LVAD recipients.
More Related Videos
03:24Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging
Published on: March 22, 2024
08:31Candida albicans Biofilm Development on Medically-relevant Foreign Bodies in a Mouse Subcutaneous Model Followed by Bioluminescence Imaging
Published on: January 27, 2015
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Endocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Endocarditis II: Clinical Features of Infective Endocarditis
Pneumonia III: Complications and Assessment
Endocarditis IV: Nursing Management